Determination of serum n-terminal pro-brain natriuretic peptide and soluble st2 receptor levels for the prediction of cardiovascular events in patients receiving «on-line» hemodiafiltration

Objective. evaluation of the possibility of determining the serum n-terminal pro-brain natriuretic peptide (nt-probnp) and soluble st2 receptor (sst2) levels for predicting cardiovascular events (CVE) in patients receiving «on-line» hemodiafiltration (HDF). material and methods. during the 16 months of the prospective study, 43 patients (60.5% men) receiving «on-line» hdf were followed-up. Two groups of patients were identified depending on the presence/absence of an simultaneous increase in two biomarkers: nt-probnp>2093 pg/ml and sst2>22 ng/ml. results. cve were detected in 11 (25.6%) patients out of 43; cve were fatal in 4 patients. repeated cve during the follow-up period were not identified. serum nt-probnp level was 1808 (757-2580) pg/ml, sst2 - 22 ± 5.9 ng/ml. among patients with a simultaneous increase in two biomarkers (n=12), cve developed in 6 (50%) patients, and among patients without an increase in nt-probnp + sst2 (n=31) - in 5 (16.i%). the incidence of cve was significantly higher in the presence of a simultaneous increase in two biomarkers: nt-probnp >2098 pg/ml and sst2 >22 ng/ml (P2098 pg/ml in combination with sst2 >22 ng/ml should be considered to be at high risk for cve.

NT-proBNP, sST2, programmed hemodialysis, hemodiafiltration, NT-proBNP, sST2, biomarkers, cardiovascular diseases